Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739335 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2S1PR5S1PR1S1PR4S1PR3 | |
| SCHEMBL934458 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2S1PR5S1PR1S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL28596153 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2S1PR5S1PR1S1PR4S1PR3 | |
| SCHEMBL1609328 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2S1PR5HSD11B1CYP1A2ALDH1A1 | |
| SCHEMBL771607 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2S1PR5HSD11B1CYP1A2ALDH1A1 | |
| SCHEMBL740141 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2S1PR5HSD11B1CYP1A2ALDH1A1 | |
| SCHEMBL855052 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2S1PR5S1PR1S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL19638092 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2S1PR5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL613075 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2S1PR5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6997154 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2S1PR5S1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006019-A1 | POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2021093817-A1 | IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-104918615-B | The method for treating hepatopathy | 扎夫根股份有限公司 | 2018-10-12 | — | — | CN | disclosed |
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2014071368-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| CN-103764641-A | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN CORP | 2014-04-30 | — | — | CN | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012154676-A9 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2012154676-A9 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2705030-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | SMN1; SMN2 4364/4885S1PR5 1622/4885S1PR1 1430/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | SMN1; SMN2 4364/4885S1PR5 1622/4885S1PR1 1430/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | SMN1; SMN2 3316/4885S1PR5 2194/4885S1PR1 2590/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | SMN1; SMN2 3316/4885S1PR5 2194/4885S1PR1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.